PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Dacomitinib→

Dacomitinib PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
1110813-31-4
Molecular formula
C24H25ClFN5O2
Molecular weight
469.94 g/mol
Drug class
Second-generation irreversible pan-human epidermal growth factor receptor (HER) tyrosine kinase inhibitor
Mechanism of action
Irreversibly inhibits EGFR/HER1, HER2 and HER4 kinase activity and selected activating EGFR mutations, blocking receptor-mediated downstream signalling and tumour-cell proliferation.
Indications / reported uses
  • First-line treatment of adults with metastatic non-small-cell lung cancer (NSCLC) with EGFR exon 19 deletion or exon 21 L858R substitution mutation, as detected by an approved test under the US product indication

Sources: US DailyMed — VIZIMPRO (dacomitinib) · FDA prescribing information · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Dacomitinib PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Dacomitinib Permitted Daily Exposure (PDE) report (the Dacomitinib PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Dacomitinib Occupational Exposure Limit (OEL) report (the Dacomitinib OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.